125 related articles for article (PubMed ID: 33926834)
1. Feasibility of ureter delineation and dose recording in the assessment of ureteric stenosis during brachytherapy for cervical cancer.
Sarwar A; Lalli N; Aughwane P; Eminowicz G
Brachytherapy; 2021; 20(4):755-764. PubMed ID: 33926834
[TBL] [Abstract][Full Text] [Related]
2. Can we reduce dose to ureters as avoidance organs for MRI based brachytherapy for cervical cancer? A dosimetric feasibility study.
Koerner SA; Baig T; Kim H; Rodríguez-López J; Keller A; Beriwal S
Brachytherapy; 2022; 21(2):202-207. PubMed ID: 34980569
[TBL] [Abstract][Full Text] [Related]
3. Ureter dose optimization during image guided brachytherapy for cervical cancer.
Sarwar A; Lalli N; Eminowicz G
Brachytherapy; 2022; 21(4):397-404. PubMed ID: 35422401
[TBL] [Abstract][Full Text] [Related]
4. Toxicities and dose-volume histogram parameters of MRI-based brachytherapy for cervical cancer.
Kim Y; Kim YJ; Kim JY; Lim YK; Jeong C; Jeong J; Kim M; Lim MC; Seo SS; Park SY
Brachytherapy; 2017; 16(1):116-125. PubMed ID: 27876378
[TBL] [Abstract][Full Text] [Related]
5. Deformable image registration for cervical cancer brachytherapy dose accumulation: Organ at risk dose-volume histogram parameter reproducibility and anatomic position stability.
Flower E; Do V; Sykes J; Dempsey C; Holloway L; Summerhayes K; Thwaites DI
Brachytherapy; 2017; 16(2):387-392. PubMed ID: 28161434
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.
Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J
Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726
[TBL] [Abstract][Full Text] [Related]
7. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.
Ribeiro I; Janssen H; De Brabandere M; Nulens A; De Bal D; Vergote I; Van Limbergen E
Radiother Oncol; 2016 Sep; 120(3):447-454. PubMed ID: 27157510
[TBL] [Abstract][Full Text] [Related]
8. Comparing organ-at-risk doses for high-dose-rate vaginal brachytherapy between three different planning workflows.
Gruhl JD; Zheng D; Longo JL; Enke C; Wahl AO
Brachytherapy; 2017; 16(2):373-377. PubMed ID: 28039010
[TBL] [Abstract][Full Text] [Related]
9. Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy.
Levitchi M; Charra-Brunaud C; Quetin P; Haie-Meder C; Kerr C; Castelain B; Delannes M; Thomas L; Desandes E; Peiffert D
Radiother Oncol; 2012 Jun; 103(3):314-21. PubMed ID: 22633813
[TBL] [Abstract][Full Text] [Related]
10. Bladder distension improves the dosimetry of organs at risk during intracavitary cervical high-dose-rate brachytherapy.
Harmon G; Chinsky B; Surucu M; Harkenrider M; Small W
Brachytherapy; 2016; 15(1):30-4. PubMed ID: 26521661
[TBL] [Abstract][Full Text] [Related]
11. Can MRI-only replace MRI-CT planning with a titanium tandem and ovoid applicator?
Harkenrider MM; Patel R; Surucu M; Chinsky B; Mysz ML; Wood A; Ryan K; Shea SM; Small W; Roeske JC
Brachytherapy; 2018; 17(5):747-752. PubMed ID: 29945764
[TBL] [Abstract][Full Text] [Related]
12. Ureteral stenosis after 3D MRI-based brachytherapy for cervical cancer - Have we identified all the risk factors?
Rodríguez-López JL; Ling DC; Keller A; Kim H; Mojica-Márquez AE; Glaser SM; Beriwal S
Radiother Oncol; 2021 Feb; 155():86-92. PubMed ID: 33065181
[TBL] [Abstract][Full Text] [Related]
13. Correlation of point B and lymph node dose in 3D-planned high-dose-rate cervical cancer brachytherapy.
Lee LJ; Sadow CA; Russell A; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):803-9. PubMed ID: 19286328
[TBL] [Abstract][Full Text] [Related]
14. CT-based 3D dose-volume parameter of the rectum and late rectal complication in patients with cervical cancer treated with high-dose-rate intracavitary brachytherapy.
Kato S; Tran DN; Ohno T; Nakano T; Kiyohara H; Ohkubo Y; Kamada T
J Radiat Res; 2010; 51(2):215-21. PubMed ID: 20339256
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
[TBL] [Abstract][Full Text] [Related]
16. The association of vagina equivalent dose in 2Gy fraction (EQD
Ruanla J; Muangwong P; Kittidachanan K; Tippanya D; Thongsuk W; Kongsa A; Galalae RM; Tharavichitkul E
Brachytherapy; 2022; 21(5):658-667. PubMed ID: 35715305
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of electronic brachytherapy in cervix cancer-A dosimetric comparison of different brachytherapy techniques.
Lozares-Cordero S; Gonzalez-Perez V; Pellejero-Pellejero S; Rodriguez-Ruiz L; Guinot-Rodriguez JL; Villafranca-Iturre E; Méndez-Villamón A; Gandía-Martínez A; Fuentemilla-Urío N; Ruggeri R
Brachytherapy; 2022; 21(4):389-396. PubMed ID: 35246391
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cervical cancer with electronic brachytherapy.
Lozares-Cordero S; Font-Gómez JA; Gandía-Martínez A; Miranda-Burgos A; Méndez-Villamón A; Villa-Gazulla D; Alba-Escorihuela V; Jiménez-Puertas S; González-Pérez V
J Appl Clin Med Phys; 2019 Jul; 20(7):78-86. PubMed ID: 31183970
[TBL] [Abstract][Full Text] [Related]
19. Calculation of dose volume parameters and indices in plan evaluation of HDR interstitial brachytherapy by MUPIT in carcinoma cervix.
Poddar J; Sharma AD; Suryanarayan U; Shah SP; Parikh A; Mehta V; Kumar T
Indian J Cancer; 2018; 55(3):238-241. PubMed ID: 30693886
[TBL] [Abstract][Full Text] [Related]
20. Deformable image registration-based contour propagation yields clinically acceptable plans for MRI-based cervical cancer brachytherapy planning.
Chapman CH; Polan D; Vineberg K; Jolly S; Maturen KE; Brock KK; Prisciandaro JI
Brachytherapy; 2018; 17(2):360-367. PubMed ID: 29331573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
